SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-279041
Filing Date
2022-11-07
Accepted
2022-11-07 16:01:31
Documents
14
Period of Report
2022-11-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d377532d8k.htm   iXBRL 8-K 25878
2 EX-99.1 d377532dex991.htm EX-99.1 10711
6 GRAPHIC g377532g1107104245833.jpg GRAPHIC 3147
  Complete submission text file 0001193125-22-279041.txt   169965

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20221107.xsd EX-101.SCH 2864
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20221107_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20221107_pre.xml EX-101.PRE 11714
8 EXTRACTED XBRL INSTANCE DOCUMENT d377532d8k_htm.xml XML 3469
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 221365338
SIC: 2836 Biological Products, (No Diagnostic Substances)